Dr Reddys Laboratories Ltd

₹ 1,173 -1.16%

16 Jan 2:24 p.m.

🔗 Website | BSE: 500124 | NSE: DRREDDY

Market Cap97,873

Current Price1,173

High / Low1,380

Stock P/E18.2

Book Value378

Dividend Yield0.67

ROCE25.8

ROE20.3

ABOUT

Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.

Stock Analysis

Description

Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, India, committed to providing access to affordable and innovative medicines through its diverse portfolio including APIs, generics, branded generics, biosimilars, and OTC products, with major therapeutic areas of focus being gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.

Key Growth Triggers

First-to-market launch of OTC Olopatadine Hydrochloride Ophthalmic Solution in the U.S. This expands the company's OTC eye-care portfolio and strengthens its presence in the U.S. market, building on existing capabilities and demonstrating strong R&D and commercialization strengths.

Order Book

Currently no data available for Order Book.

Key Red Flags

Currently no data available for Key Red Flags.

Key Dates To Watch

Currently no data available for Key Dates To Watch.

Peer Comparison

S.No.	Name	Current Price (Rs.)	Price to Earning	Market Capitalization (Rs.Cr.)	Dividend yield (%)	Net Profit latest quarter (Rs.Cr.)	YOY Quarterly profit growth (%)	Sales latest quarter (Rs.Cr.)	YOY Quarterly sales growth (%)	Return on capital employed (%)	Sales (Rs.Cr.)	OPM (%)	Profit after tax (Rs.Cr.)	Profit after tax latest quarter (Rs.Cr.)	Price to book value	Return on assets (%)	Debt to equity
1.	Sun Pharma.Inds.	1662.90	34.53	398985.47	0.95	3124.95	2.56	14478.31	8.93	20.21	54964.01	30.12	11543.96	3117.95	5.11	12.97	0.07
2.	Divi's Lab.	6240.85	66.65	165674.92	0.47	689.00	35.10	2715.00	16.12	20.44	10029.00	32.37	2485.00	689.00	10.73	13.53	0.01
3.	Torrent Pharma.	4001.45	62.52	135427.25	0.81	591.00	32.49	3302.00	14.30	27.05	12248.00	32.60	2166.53	600.17	16.04	13.26	0.33
4.	Cipla	1396.50	20.73	112805.32	0.94	1353.37	3.73	7589.44	7.64	22.72	28349.57	25.40	5441.14	1351.17	3.40	14.72	0.01
5.	Lupin	2173.25	23.04	99273.75	0.55	1484.83	73.34	7047.51	24.23	21.30	24750.69	27.25	4324.63	1477.92	5.09	12.41	0.32
6.	Dr Reddy's Labs	1172.65	18.24	97872.92	0.67	387.30	-79.42	4618.60	-31.03	25.75	23006.00	30.22	5398.60	387.30	3.14	15.68	0.13
7.	Mankind Pharma	2181.80	51.54	90065.80	0.04	520.18	-22.00	3697.16	20.77	15.98	13545.67	24.12	1748.55	511.51	5.98	8.89	0.55

Quarterly Results

Figures in Cr.

	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	4,880	3,898	4,554	5,437	4,839	4,103	5,105	5,841	6,696	5,015	5,563	7,810	4,619
YOY Sales Growth %	27.64%	12.01%	24.13%	49.76%	-0.85%	5.27%	12.09%	7.43%	38.39%	22.23%	8.97%	33.7%	-31.03%
Expenses	3,078	3,222	3,493	3,210	3,210	3,447	3,726	3,888	3,975	3,823	4,120	3,972	4,138
Material Cost %	24.78%	31.43%	29.21%	21.74%	23.66%	31.94%	27.46%	26.11%	22.37%	29.57%	28.03%	20.31%	37.47%
Employee Cost %	14.55%	18.18%	16.8%	13.61%	16.2%	19.07%	15.27%	14.65%	12.55%	15.84%	14.33%	11.36%	18.79%
Operating Profit	1,803	675	1,061	2,228	1,629	656	1,379	1,953	2,722	1,192	1,443	3,837	480
OPM %	37%	17%	23%	41%	34%	16%	27%	33%	41%	24%	26%	49%	10%
Other Income	118	51	115	234	223	228	213	218	208	235	414	398	364
Exceptional items	—	—	—	—	—	—	—	—	—	—	—	—	—
Other income normal	118	51	115	234	223	228	213	218	208	235	414	398	364
Interest	2	3	3	4	6	6	6	7	28	43	31	19	33
Depreciation	226	239	237	237	246	246	246	250	260	265	264	280	295
Profit before tax	1,693	485	937	2,220	1,601	632	1,339	1,914	2,641	1,119	1,562	3,936	516
Tax %	34%	33%	28%	26%	25%	25%	23%	26%	29%	24%	23%	25%	25%
Net Profit	1,116	325	672	1,639	1,193	475	1,035	1,417	1,882	849	1,201	2,961	387
EPS in Rs	13.41	3.9	8.08	19.69	14.3	5.7	12.41	16.99	22.56	10.18	14.39	35.48	4.64

Profit & Loss

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	9,728	10,011	10,292	9,720	9,359	10,626	11,850	13,349	14,405	16,962	19,484	23,115	23,006
Sales Growth %	—	—	—	—	—	—	—	—	—	—	—	—	—
Expenses	6,950	7,608	8,219	7,899	7,990	8,290	8,967	10,212	11,803	12,724	13,557	15,691	16,053
Material Cost %	—	—	—	—	—	—	—	—	—	—	—	—	—
Raw material cost	—	—	—	—	—	—	—	—	—	—	—	—	—
Change in inventory	—	—	—	—	—	—	—	—	—	—	—	—	—
Manufacturing Cost %	—	—	—	—	—	—	—	—	—	—	—	—	—
Employee Cost %	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Cost %	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating Profit	2,778	2,403	2,073	1,820	1,370	2,336	2,883	3,137	2,602	4,238	5,926	7,425	6,953
OPM %	29%	24%	20%	19%	15%	22%	24%	24%	18%	25%	30%	32%	30%
Other Income	135	211	317	516	164	202	730	801	474	568	862	961	1,412
Exceptional items	—	—	—	—	—	—	—	—	—	—	—	—	—
Other income normal	—	—	—	—	—	—	—	—	—	—	—	—	—
Interest	78	64	64	57	63	57	48	47	38	17	22	110	127
Depreciation	380	490	650	735	774	781	789	835	814	923	976	1,039	1,104
Profit before tax	2,454	2,060	1,677	1,544	697	1,701	2,776	3,056	2,224	3,866	5,791	7,236	7,134
Tax %	21%	18%	18%	10%	19%	25%	-6%	28%	27%	32%	25%	26%	—
Net Profit	1,933	1,679	1,374	1,384	567	1,277	2,938	2,186	1,623	2,613	4,342	5,349	5,399
Exceptional items AT	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit excl Excep	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit for PE	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit for EPS	—	—	—	—	—	—	—	—	—	—	—	—	—
EPS in Rs	22.73	19.71	16.11	16.7	6.83	15.38	35.36	26.29	19.51	31.38	52.06	64.11	64.69
Dividend Payout %	16%	20%	25%	24%	59%	26%	14%	19%	31%	26%	15%	12%	—

Balance Sheet

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	85	85	85	83	83	83	83	83	83	83	83	83	84
Reserves	9,244	10,549	11,993	11,518	11,725	12,601	15,109	16,900	18,253	20,391	24,157	28,773	31,429
Borrowings	2,666	3,126	3,085	2,355	2,589	1,065	1,457	1,214	2,205	51	793	3,493	3,979
Long term Borrowings	902	939	994	485	488	345	19	0	0	0	0	0	0
Short term Borrowings	1,763	2,186	2,090	1,870	2,101	546	1,044	1,181	2,171	1	710	3,386	3,663
Lease Liabilities	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Borrowings	2	1	2	0	0	173	394	0	0	0	0	0	—
Other Liabilities	2,513	2,696	2,422	2,491	2,704	2,499	2,827	3,431	3,954	4,850	5,326	5,941	7,099
Trade Payables	842	716	719	779	1,061	1,032	1,068	1,336	1,666	1,764	2,045	1,993	2,534
Advance from Customers	0	0	23	24	19	52	49	30	59	40	23	41	—
Other liability items	1,671	1,980	1,680	1,689	1,624	1,416	1,710	2,065	2,229	3,045	3,258	3,907	4,566
Total Liabilities	14,508	16,456	17,585	16,447	17,100	16,248	19,476	21,630	24,496	25,375	30,359	38,291	42,591
Fixed Assets	2,748	3,249	4,438	4,842	4,717	4,683	4,434	5,844	6,150	7,195	7,589	8,232	9,813
Land	126	126	128	135	167	167	167	177	177	178	201	210	—
Building	1,118	1,229	1,440	1,638	1,721	1,843	1,937	1,989	2,071	2,218	2,328	2,544	—
Plant Machinery	2,422	2,885	4,540	5,318	5,698	6,044	6,353	6,631	7,444	8,432	9,152	10,254	—
Equipments	620	708	229	278	0	0	0	0	0	0	0	0	—
Furniture & fittings	—	—	—	—	—	—	—	—	—	—	—	—	—
Vehicles	21	18	21	15	13	15	46	52	58	83	104	108	—
Intangible Assets	64	65	188	191	32	32	32	85	85	85	85	85	2,805
Other fixed assets	87	225	940	994	1,183	1,234	1,222	2,939	2,993	3,554	3,791	3,912	—
Gross Block	4,900	5,816	7,580	8,675	9,224	9,774	10,216	12,345	13,349	15,137	16,297	17,715	—
Accumulated Depreciation	2,151	2,566	3,142	3,833	4,506	5,091	5,782	6,501	7,199	7,941	8,708	9,482	—
CWIP	576	488	616	540	675	400	412	901	1,200	924	1,211	2,197	1,706
Investments	2,806	3,862	5,076	3,102	3,636	3,934	5,486	4,649	4,937	7,440	7,321	13,194	14,416
Other Assets	8,377	8,856	7,455	7,963	8,072	7,231	9,145	10,235	12,208	9,815	14,239	14,668	16,655
Inventories	1,592	1,723	1,700	1,810	1,857	2,016	2,190	2,820	3,348	3,043	4,019	4,576	4,862
Trade receivables	4,562	4,712	3,890	4,405	4,204	3,718	4,639	4,080	4,945	4,289	4,624	5,959	6,635
Receivables under 6m	—	—	—	—	—	—	—	—	—	—	—	—	—
Receivables over 6m	—	—	—	—	—	—	—	—	—	—	—	—	—
Prow for Doubtful	—	—	—	—	—	—	—	—	—	—	—	—	—
Cash Equivalents	665	901	202	67	121	113	39	1,646	2,030	646	1,217	977	1,041
Loans & Advances	—	—	—	—	—	—	—	—	—	—	—	—	—
Other Assets items	—	—	—	—	—	—	—	—	—	—	—	—	—
Total Assets	14,508	16,456	17,585	16,447	17,100	16,248	19,476	21,630	24,496	25,375	30,359	38,291	42,591

Cash Flows

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	906	1,786	2,747	1,016	1,539	2,762	1,839	3,514	1,339	5,053	3,450	4,225
Profit from operations	3,473	2,656	2,765	2,193	1,661	2,659	3,458	3,330	3,069	4,912	6,393	8,050
Receivables	-1,827	-47	624	-656	336	455	-1,093	714	-866	657	-341	-1,345
Inventory	-197	-402	-126	-318	-244	-159	-175	-583	-790	-100	-1,217	-834
Payables	75	-127	2	63	274	-20	37	268	330	98	280	-52
Loans Advances	—	—	—	—	—	—	—	—	—	—	—	—
Other WC items	-74	186	-121	56	-315	66	89	234	84	269	-346	-8
Working capital changes	-2,024	-391	379	-854	51	342	-1,142	633	-1,241	924	-1,624	-2,239
Direct taxes	-543	-479	-397	-323	-174	-239	-477	-448	-489	-783	-1,320	-1,586
Cash from Investing Activity	-874	-2,031	-1,919	1,430	-1,180	-546	-1,689	-1,454	-1,990	-3,403	-3,429	-5,697
Fixed assets purchased	-872	-962	-1,084	-985	-798	-653	-474	-1,094	-1,366	-1,571	-1,594	-2,477
Fixed assets sold	27	8	1	2	12	88	6	490	9	25	88	43
Investments purchased	-3,581	-3,595	-6,532	-4,850	-6,062	-7,727	-12,273	-6,952	-9,112	-12,032	-13,758	-22,474
Investments sold	3,107	2,610	6,420	6,953	5,628	7,479	10,919	7,486	8,273	10,077	11,747	25,504
Interest received	89	73	108	62	34	82	59	163	157	100	182	400
Redeemp Cnce of Shares	—	—	—	—	—	—	—	—	—	—	—	—
Acquisition of companies	0	0	0	0	0	0	0	0	0	-46	0	0
Other investing items	355	-306	-852	-70	6	184	34	-1,547	48	44	2	60
Cash from Financing Activity	28	189	-693	-2,582	-304	-2,223	-224	-794	506	-2,697	68	1,591
Redemption of debentures	-508	0	0	0	0	0	0	0	0	0	0	0
Proceeds from borrowings	4,440	2,737	2,576	0	165	0	463	153	968	0	709	2,584
Repayment of borrowings	-3,523	-2,122	-2,787	-614	-0	-1,705	-180	-374	0	-2,170	0	0
Interest paid fin	-83	-69	-75	-64	-71	-64	-53	-62	-64	-46	-33	-179
Dividends paid	-298	-357	-407	-335	-399	-400	-391	-415	-415	-498	-665	-666
Financial liabilities	0	0	0	0	0	0	-16	-4	-17	-20	-24	-28
Other financing items	0	0	0	-1,569	0	-54	-47	-119	0	0	0	-139
Net Cash Flow	60	-56	135	-135	54	-8	-74	1,266	-146	-1,047	89	118

Ratios

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	171	172	138	165	164	128	143	112	125	92	87	94
Inventory Days	233	223	234	256	258	242	224	250	242	219	291	275
Days Payable	123	93	99	110	147	124	109	118	121	127	148	120
Cash Conversion Cycle	281	302	273	311	274	246	257	243	247	184	230	250
Working Capital Days	115	99	82	112	98	125	116	95	89	95	130	63
ROCE %	23%	16%	12%	11%	5%	12%	19%	15%	12%	19%	25%	26%

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	26.69%	26.69%	26.69%	26.66%	26.65%	26.65%	26.65%	26.64%	26.64%	26.64%	26.64%	26.64%
APS Trust	—	20.62	20.62	20.59	20.59	20.59	0	0	0	0	0	0
APS Trust (Trustees: G_ V_ Prasad and Satish Reddy Kallam)	20.62	—	—	—	—	—	—	—	—	—	—	—
Anuradha Gunupati	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Deepti Reddy Kallam	0	0	0	0	0	0	0	0	0	0	0	0
G V Prasad	0	0	0	0	0	0	11.52	11.52	11.52	11.52	11.51	0
G Vani Sanjana Reddy	0	0	0	0	0	0	0	0	0	0	0	0
GVP Family Trust	—	—	—	—	—	—	—	—	—	—	—	11.51
Gunupati Mallika Reddy	0	0	0	0	0	0	0	0	0	0	0	0
Gunupati Venkateswara Prasad Huf	—	1.53	1.53	1.52	1.52	1.52	1.52	1.52	1.52	1.52	1.52	1.52
Gunupati Venkateswara Prasad Huf (Gunupati Venkate___	1.53	—	—	—	—	—	—	—	—	—	—	—
K Shravya Reddy	0	0	0	0	0	0	0	0	0	0	0	0
K Vishal Reddy	0	0	0	0	0	0	0	0	0	0	0	0
Kallam Satish Reddy Huf	—	3.32	3.32	3.31	3.31	3.31	3.31	3.31	3.31	3.31	3.31	3.31
Kallam Satish Reddy Huf (Kallam Satish Reddy)	3.32	—	—	—	—	—	—	—	—	—	—	—
Samrajyam Reddy Kallam	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	0.67	—	—	—
Satish Reddy Kallam	0.54	0.54	0.54	0.54	0.54	0.54	9.61	9.6	9.6	10.27	10.27	1.21
Sharathchandra Reddy Gunupati	0	0	0	0	0	0	0	0	0	0	0	0
VSD Family Trust	—	—	—	—	—	—	—	—	—	—	—	9.06
VSD Holdings & Advisory LLP	0	0	0	0	0	0	0	0	0	0	0	0
FIIs	27.29%	27.25%	26.99%	28.19%	28.62%	29.13%	27.68%	27.53%	26.85%	25.75%	25.33%	24.69%
First Sentier Investors Icvc - Stewart Investors A___	2.2	2.2	2.2	2.32	2.32	2.32	2.32	2.32	2.32	1.45	—	—
Government Of Singapore	1.36	1.3	1.24	1.21	1.07	1.02	—	—	—	—	—	—
Government Pension Fund Global	1.06	1.01	—	—	—	—	—	—	—	—	—	—
DIIs	23.38%	23.05%	21.99%	21.04%	18.65%	18.31%	20.72%	21.48%	22.89%	25.63%	26.73%	27.99%
Hdfc Life Insurance Company Limited	1.03	1.04	1.04	1.04	—	—	—	—	—	—	—	—
Hdfc Trustee Company Ltd_ A/C Hdfc Nifty 50 Etf	1.36	1.62	1.77	1.75	1.81	1.62	1.75	1.34	—	—	—	—
Icici Prudential Sensex Index Fund	1.05	1.02	—	—	—	—	—	—	—	—	—	—
Icici Prudential Value Discovery Fund	—	—	—	—	—	—	1.17	2.09	2.38	3.79	4.15	4.34
Life Insurance Corporation Of India P & Gs Fund	8.95	9.79	9.72	7.34	5.16	5.05	5.52	5.6	6.5	7.19	8.3	9.69
Mirae Asset Nifty India Manufacturing Etf	—	—	—	—	—	—	1.11	—	—	—	—	—
Mirae Asset Nifty500 Multicap 50:25:25 Etf	—	—	—	—	—	—	—	—	—	—	1.21	1.25
Nippon Life India Trustee Ltd-A/C Nippon India Etf___	1.16	1.04	—	—	—	—	—	—	—	—	—	—
Nippon Life India Trustee Ltd-A/C-Nippon India Nif___	—	—	—	—	—	—	1.02	1.33	1.83	1.95	1.92	1.78
Nps Trust-A/C Sbi Pension Fund Scheme Tax Saver-Tier 2	—	—	—	2.09	2.19	2.3	2.53	2.66	2.55	2.45	2.25	2.49
Parag Parikh Flexi Cap Fund	—	—	—	—	—	—	—	—	—	1.28	1.31	1.45
Sbi Nifty Index Fund	—	—	—	—	—	—	1.29	1.49	1.29	1.37	1.43	1.33
Sbi-Etf Nifty 50	1.57	1.54	1.68	1.67	1.46	1.42	—	—	—	—	—	—
Government	—	—	—	—	—	—	—	—	—	—	—	—
Public	22.36%	22.78%	24.11%	23.93%	25.89%	25.73%	24.78%	24.2%	23.46%	21.69%	21.04%	20.45%
J P Morgan Chase Bank NA	10.53	11.3	12.54	14.02	15.33	15.35	14.59	14.22	13.23	11.54	11.04	10.83
Nps Trust-A/C Hdfc Pension Management Company Ltd ___	1.89	1.94	2.13	—	—	—	—	—	—	—	—	—
Others	0.25%	0.22%	0.21%	0.18%	0.18%	0.17%	0.17%	0.16%	0.16%	0.29%	0.26%	0.25%
No. of Shareholders	2,46,788	2,32,715	2,46,769	2,43,445	2,57,794	2,55,500	2,67,694	3,10,403	4,03,669	4,59,605	4,51,929	4,49,216

News & Updates

BSE Announcements

Direct from BSE filings, AI summarised

Dr. Reddy's Laboratories Announces First-to-Market Launch of OTC Olopatadine Hydrochloride Ophthalmic Solution in the U.S.

14 Jan 2026

Dr. Reddy's Laboratories Receives USFDA Post-Application Action Letter for Bachupally Facility

10 Jan 2026

Dr. Reddy's Laboratories Announces Q3 FY26 Results Release and Earnings Call for January 21, 2026

8 Jan 2026

Dr. Reddy's Laboratories Files Routine Compliance Certificate for Q4 FY26

6 Jan 2026

Dr. Reddy's Laboratories Issues Notice on Lost Share Certificates

6 Jan 2026

Other Websites

External media mentions

Weight-Loss Drug War: Generics Loom as Novo, Lilly Face Fierce Competition

18 Jan 2026

Budget Buzz, Global Data, Earnings Storm: India Week Ahead

16 Jan 2026

Cipla Shares Tumble 3% on Nuvama Downgrade, US Drug Supply Hit

16 Jan 2026

Stocks to Watch Jan 16: Infosys Profit Dips, ICICI Pru AMC Surges as Earnings Season Unfolds

16 Jan 2026

Indian Markets Slip Second Day; Infosys Misses Profit Despite Guidance

16 Jan 2026

News Articles

Editorial & research coverage

Weight-Loss Drug War: Generics Loom as Novo, Lilly Face Fierce Competition

18 Jan 2026

Indian Markets Slip Second Day; Infosys Misses Profit Despite Guidance

16 Jan 2026

Pharma Q3: Revlimid Loss Hits US Sales, Domestic Growth Offers Cushion

15 Jan 2026

Dr Reddy's FDA-Approved Generic Eye Drop Launched in US

14 Jan 2026

Dr Reddy's Scores US First With Generic Pataday Eye Drop Launch

14 Jan 2026

Documents

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release

1d - Jan 14, 2026: Launched OTC Olopatadine 0.7% generic (Pataday equivalent) in U.S.; Pataday $69.9M sales; 2.5mL bottle.

Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

10 Jan - Dr. Reddy's received USFDA PAAL for Bachupally biologics facility; will address queries (Jan 10, 2026).

Announcement under Regulation 30 (LODR)-Press Release / Media Release

8 Jan - Q3FY26 results to be released Jan 21, 2026; earnings call 19:30 IST/9:00 ET; transcript available.

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

null

Announcement under Regulation 30 (LODR)-Newspaper Publication

null

Annual Reports

FY Financial Year 2025

(from bse)

FY Financial Year 2024

(from bse)

FY Financial Year 2023

(from bse)

FY Financial Year 2022

(from bse)

FY Financial Year 2021

(from bse)

FY Financial Year 2020

(from bse)

FY Financial Year 2019

(from bse)

FY Financial Year 2018

(from bse)

FY Financial Year 2017

(from bse)

FY Financial Year 2016

(from bse)

FY Financial Year 2015

(from bse)

FY Financial Year 2014

(from bse)

FY Financial Year 2013

(from nse)

FY Financial Year 2013

(from bse)

FY Financial Year 2012

(from bse)

Credit Ratings

Rating update

9 Jan from icra

Rating update

27 Dec 2024 from icra

Rating update

4 Jun 2024 from icra

Rating update

28 Sep 2023 from icra

Rating update

28 Jul 2022 from icra

Rating update

29 Jul 2021 from icra

Concalls

Oct 2025

Transcript PPT Audio

Jul 2025

Transcript PPT Audio

May 2025

Transcript Audio

Jan 2025

Transcript Audio

Nov 2024

Transcript Audio

Aug 2024

Transcript

Jul 2024

Transcript

May 2024

Transcript

Feb 2024

Transcript

Nov 2023

Transcript

Jul 2023

Transcript PPT

May 2023

Transcript

Jan 2023

Transcript

Nov 2022

Transcript

Jun 2022

Transcript PPT

Feb 2022

Transcript

Nov 2021

Transcript

Aug 2021

Transcript

May 2021

Transcript

May 2020

Transcript

Jan 2020

Transcript

Oct 2019

Transcript

Jul 2019

Transcript

Apr 2017

Transcript

Oct 2016

Transcript

Jul 2016

Transcript

Apr 2016

Transcript

Nov 2015

Transcript

Dr Reddys Laboratories Ltd

ABOUT

Stock Analysis

Description

Key Growth Triggers

Order Book

Key Red Flags

Key Dates To Watch

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

News & Updates

BSE Announcements

Other Websites

News Articles

Documents

Announcements

Annual Reports

Credit Ratings

Concalls